{"id":"NCT04174365","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-30","primaryCompletion":"2022-08-08","completion":"2022-09-09","firstPosted":"2019-11-22","resultsPosted":"2025-08-28","lastUpdate":"2025-08-28"},"enrollment":119,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Irritability Associated With Autism Spectrum Disorder (ASD)"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":["brexpiprazole, OPC-34712 and LuAF41156"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.","primaryOutcome":{"measure":"Mean Change From Baseline to Week 8 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Brexpiprazole","deltaMin":-10.1,"sd":1.28},{"arm":"Placebo","deltaMin":-8.87,"sd":1.25}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4597"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Somnolence","Headache","Vomiting"]}}